Macular Edema and Macular Degeneration Market to Reach $22.51 Billion by 2034

The global macular edema and macular degeneration market, valued at $10.33 billion in 2023, is on track to grow at a remarkable compound annual growth rate (CAGR) of 7.34%, reaching $22.51 billion by 2034. This substantial market expansion is being fueled by rising treatment innovations, an increasing global prevalence of related diseases, and a surge in technological advancements in diagnostics and therapies.

Download White Paper: https://www.towardshealthcare.com/download-statistics/5375

Market Overview and Key Drivers

The macular edema and macular degeneration market is witnessing rapid growth, largely due to the growing incidence of age-related macular degeneration (AMD), which is a leading cause of vision loss among older adults, and diabetic macular edema (DME), a complication of diabetic retinopathy affecting millions worldwide.

One of the most significant drivers of this market's growth is the increasing prevalence of diabetic retinopathy (DR) and DME, which are among the primary causes of vision impairment in diabetic patients. Nearly 745,000 Americans suffer from diabetic macular edema, with more than half of them remaining undiagnosed. Furthermore, as the global population ages, the number of individuals affected by age-related macular degeneration is expected to rise significantly, intensifying the need for advanced treatment options.

Innovations in treatment are another key factor driving market growth. Leading pharmaceutical companies are advancing therapies such as vascular endothelial growth factor (VEGF) inhibitors, corticosteroids, and nonsteroidal anti-inflammatory drugs (NSAIDs), along with surgical interventions. Moreover, the introduction of gene therapy, which involves delivering anti-VEGF directly to the retina using gene-modified viral vectors, promises long-term treatment solutions, reducing the need for frequent ocular injections.

In addition, artificial intelligence (AI) is playing a pivotal role in the diagnosis and management of macular diseases. AI tools, particularly deep learning (DL) algorithms, are enhancing diagnostic accuracy and treatment planning by enabling better prediction of patient responses to therapies, optimizing anti-VEGF treatments, and reducing healthcare costs. AI-based diagnostic tools, such as the IDx-DR system, have already been FDA-approved, providing clinicians with automated, accurate screening for diabetic retinopathy.

Get the latest insights on healthcare industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Recent Developments and Innovations

In the past year, several major pharmaceutical companies and biotechnology firms have introduced new advancements in the market, underscoring the dynamic nature of this sector. Notable developments include:

Regeneron Pharmaceuticals' approval of EYLEA HD (aflibercept) 8 mg by the FDA in August 2023, for the treatment of wet AMD, DME, and diabetic retinopathy.

Biocon Biologics Ltd's approval for Yesafili, a biosimilar replacement for aflibercept, by the U.S. Food and Drug Administration (FDA) in May 2024, marking a significant step toward more affordable treatment options.

The ongoing development of gene therapies for AMD, such as those being researched by REGENXBIO for diabetic retinopathy and DME.

Additionally, advancements in portable ophthalmology devices such as Kubota Vision's eyeMO, which provides cost-effective, at-home monitoring for eye diseases, are expected to increase accessibility to eye care and improve patient outcomes.

Regional Insights

The North American region is expected to dominate the market due to the high prevalence of DME and the widespread adoption of AI-driven diagnostic tools. In the United States alone, approximately 37 million adults live with diabetes, with about one-third of them developing DME. This growing patient base, combined with the increasing availability of AI technologies for early diagnosis, is expected to continue driving market growth in the region.

Meanwhile, Europe is also seeing strong market growth, especially as the aging population increases the prevalence of both AMD and DME. The European Union is actively working to improve healthcare access and treatment availability for vulnerable populations, which is expected to fuel the market in the coming years.

Treatment Type and Application Segmentation

By treatment type, the drug therapy segment holds the largest market share, with anti-VEGF therapies being the most widely adopted treatment for both DME and wet AMD. However, the laser treatment segment is growing rapidly, driven by new advancements in photocoagulation therapies, which remain the gold standard for treating macular edema.

In terms of application, macular degeneration remains the dominant segment, driven by its high prevalence among the elderly. However, the diabetic macular edema segment is the fastest-growing, largely due to the rising global incidence of diabetes and the increasing need for effective treatments.

Future Market Outlook

The macular edema and macular degeneration market is poised for continued growth, with ongoing innovations in gene therapies, biosimilars, and AI-driven diagnostics offering promising solutions for patients worldwide. As advancements in treatment technologies continue to evolve, there is a clear opportunity for pharmaceutical companies, healthcare providers, and researchers to play a pivotal role in transforming the lives of millions suffering from these debilitating eye diseases.

The development of new therapies and treatments, coupled with the ongoing global healthcare initiatives to address the increasing prevalence of diabetic macular edema and age-related macular degeneration, positions the market to thrive in the years to come. With substantial investments in research and development, the market is expected to witness further breakthroughs that will redefine the future of eye care.

Review the Full TOC for the Macular Edema and Macular Degeneration Market Report: https://www.towardshealthcare.com/table-of-content/macular-edema-and-macular-degeneration-market-sizing

Top Companies in the Macular Edema and Macular Degeneration Market

1. Kubota Pharmaceutical Holdings Co. Ltd
o Kubota Pharmaceutical Holdings is a leading player in the ophthalmic space, focusing on the development of advanced therapies for eye diseases, including macular edema and macular degeneration. The company is at the forefront of clinical trials for innovative treatment solutions.

2. Alimera Sciences Inc
o Alimera Sciences is known for its development and commercialization of sustained-release intravitreal corticosteroid therapies. Their flagship product, ILUVIEN, is a key player in the management of diabetic macular edema (DME), and the company continues to focus on expanding its portfolio of retinal disease treatments.

3. AbbVie Inc
o AbbVie, a major pharmaceutical company, has a robust portfolio in ophthalmology, including treatments for wet age-related macular degeneration (AMD) and DME. Humira and Vabysmo (a VEGF inhibitor) are among the key products addressing these conditions.

4. Novartis AG
o Novartis is a global leader in eye care, with notable therapies such as Beovu (brolucizumab) for AMD and DME. The company's innovative approach to retinal diseases continues to contribute significantly to the treatment landscape for macular edema and macular degeneration.

5. F. Hoffmann-La Roche Ltd
o Roche, through its division Genentech, is a prominent player in the macular degeneration and macular edema markets. Its products like Lucentis and Susvimo are widely used for treating wet AMD and DME, making it a critical player in the space.

6. Regeneron Pharmaceuticals Inc.
o Regeneron Pharmaceuticals is renowned for its groundbreaking treatment for wet AMD and DME, EYLEA (aflibercept). The company continues to lead in innovation with new product developments and ongoing clinical trials targeting retinal diseases.

7. RegenX Bio Inc.
o RegenX Bio is at the cutting edge of gene therapy for retinal diseases, including macular degeneration. The company is working on therapies using adeno-associated virus (AAV) vectors to deliver gene-based treatments for diseases like wet AMD and DME.

8. GlaxoSmithKline Plc
o GSK is involved in the research and development of eye care treatments, focusing on both macular degeneration and macular edema. Their portfolio includes therapies that aim to address unmet needs in the ophthalmic space.

9. Bayer AG
o Bayer is a major player in the global ophthalmology market, offering Eylea (aflibercept) for DME and AMD, in partnership with Regeneron. The company is also involved in the development of other retinal disease treatments and solutions.

10. Bausch Health Companies Inc.
o Bausch Health is focused on delivering healthcare solutions for eye conditions, including macular edema and macular degeneration. The company offers treatments for retinal diseases and continues to innovate in the eye care market.

Segments Covered in the Macular Edema and Macular Degeneration Market

1. By Treatment Type

o Drug Therapy: This includes injectable therapies such as anti-VEGF agents (vascular endothelial growth factor inhibitors), corticosteroids, and gene therapies. These treatments aim to reduce retinal swelling and prevent vision loss.
o Laser Treatment: Photocoagulation using laser therapy is employed to treat conditions like macular edema, particularly in cases where drug therapy is not sufficient. Laser therapy remains a key approach in managing macular edema caused by retinal vein occlusion or other conditions.

2. By Application

o Macular Edema
Diabetic Macular Edema (DME): DME is one of the leading causes of vision loss in diabetic patients. Treatments focus on controlling fluid leakage and improving vision outcomes.
Cystoid Macular Edema (CME): CME occurs as a complication of eye surgery or retinal conditions. It is treated with anti-inflammatory medications and sometimes laser therapy.
o Macular Degeneration
Dry Age-Related Macular Degeneration (AMD): A common condition that causes gradual vision loss due to the breakdown of light-sensitive cells in the macula. There is currently no cure, but treatment focuses on slowing progression.
Wet Age-Related Macular Degeneration (AMD): This more aggressive form of AMD involves abnormal blood vessels growing under the retina, leading to vision loss. Treatments often include anti-VEGF injections to inhibit vessel growth and leakage.

3. By End User

o Hospitals: Hospitals play a central role in the treatment of advanced cases of macular degeneration and macular edema, offering both surgical interventions and advanced drug therapies.
o Clinics: Specialized clinics, including retina-focused ophthalmology centers, offer outpatient services for the diagnosis and management of retinal diseases, including the administration of injections for macular edema and macular degeneration.
o Others: This category includes home-based treatment devices, mobile ophthalmology units, and other alternative care facilities.

4. By Geography

o North America: This region is expected to hold the largest share of the market due to the high prevalence of diabetes and AMD, as well as the advanced healthcare infrastructure and adoption of cutting-edge treatments like AI-based diagnostics.
o Europe: Europe is expected to experience significant market growth due to an aging population, increasing prevalence of diabetic eye diseases, and investments in healthcare technologies.
o Asia Pacific: The market in Asia Pacific is expanding rapidly, driven by rising healthcare access, increasing diabetes rates, and growing awareness of eye diseases.
o Middle East & Africa: The market in the Middle East and Africa is growing due to improvements in healthcare infrastructure and rising awareness of macular diseases.
o Latin America: Latin America shows potential for growth in macular edema and macular degeneration treatments, as healthcare access improves and the prevalence of diabetes increases.

Acquire our comprehensive analysis today @ https://www.towardshealthcare.com/price/5375

Baner

About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Browse our Brand-New Journals:

Towards Packaging: https://www.towardspackaging.com

Towards Automotive: https://www.towardsautomotive.com

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Get Our Freshly Printed Chronicle: https://www.healthcarewebwire.com

This release was published on openPR.